The Lynx Group
Cholangiocarcinoma News

IDH1 Mutation Detection in ctDNA and Association with Clinical Response in Patients with Advanced iCCA from Phase 3 ClarIDHy

Web Exclusives — May 30, 2020

Mutations in IDH1 are detected in approximately 13% of patients with intrahepatic cholangiocarcinoma (iCCA). ClarIDHy was a global, phase 3, double-blind study in previously treated patients with advanced mutated IDH1 iCCA.1 ClarIDHy tested ivosidenib, a first-in-class, oral inhibitor of the mutant IDH1 (mIDH1) protein versus placebo in previously treated patients. Ivosidenib demonstrated an improvement in progression-free survival (PFS) versus placebo (hazard ratio, 0.37; P <.001).2 Feasibility of mIDH1 detection in plasma circulating tumor cells (ctDNA) from patients with iCCA was demonstrated in this study and was highly concordant with mutation status in tumor tissue. This analysis was extended to the larger patient cohort from ClarIDHy, and longitudinal mIDH1 detection from ctDNA was assessed and correlated with clinical response.

Formalin-fixed, paraffin-embedded tissues were used to analyze for confirmation of mIDH1 detection. Pretreatment plasma samples from all patients were collected, and longitudinal samples from patients enrolled were obtained on day 1 of each treatment cycle. mIDH1 detection in plasma ctDNA and tissue was concordant in 92% (193/210) of samples screened. Longitudinal analysis with biomarker data available as of January 2020 demonstrated IDH1-MC in plasma from 10 ivosidenib-treated patients with PFS ≥2.7 months (n = 36) versus 0 patients with PFS <2.7 months (n = 55).

The authors concluded that the feasibility of mIDH1 detection in plasma ctDNA from patients with iCCA was demonstrated and was highly concordant with mutation status in tumor tissue. ClinicalTrials.gov number NCT02989857.

References

  1. Aguado E, et al. ASCO 2020. Abstract 4576.
  2. Abou-Alfa G, et al. Ann Oncol. 2019;30(suppl_5):v851-v934.

Related Items

FGFR Inhibition in Cholangiocarcinoma: Overcoming Acquired Resistance
December 2020, Vol 1, No 3
In April 2020, the FDA granted accelerated approval to pemigatinib (Pemazyre), the first targeted therapy for cholangiocarcinoma (CCA). The FGFR inhibitor was approved for adults with CCA and FGFR2 fusion.
Emerging Molecular Targets in Cholangiocarcinoma: IDH1, HER2, BRAF, and Beyond
December 2020, Vol 1, No 3
Targeted therapy has improved survival for patients with cancer across a broad spectrum of disease sites, but until recently, progress has been slow in the treatment of patients with cholangiocarcinoma (CCA).
The Oncology Pipeline Offers Hope for Patients with Cholangiocarcinoma
December 2020, Vol 1, No 3
Despite the onslaught of the COVID-19 pandemic, researchers are hard at work to develop innovative therapies that will make a difference in the lives of patients with cancer.
Genomic Testing in Cholangiocarcinoma: Look for Actionable Molecular Alterations
December 2020, Vol 1, No 3
At the 2020 Cholangiocarcinoma Summit, Nabeel El-Bardeesy, PhD, Associate Professor, Medicine, Harvard Medical School, and Associate Geneticist, Center for Cancer Research, Massachusetts General Hospital Cancer Center, Boston, MA, moderated a session titled “Molecular Biomarkers in CCA: Focus on Current and Emerging Technologies.” The session focused on how best to integrate the array of genomic testing platforms into clinical practice. The session included 2 presenters who discussed this topic.
Increasing Number of Biomarkers Being Studied in Cholangiocarcinoma Clinical Trials
December 2020, Vol 1, No 3
At diagnosis, the majority of patients with intrahepatic cholangiocarcinoma (CCA) present with advanced disease and a poor prognosis. Comprehensive genomic profiling (CGP) of intrahepatic CCA has revealed multiple potential therapeutic targets, including FGFR2, ERBB2 (HER2), and IDH1. Therefore, performing CGP early in the disease course is critical to increasing first-line clinical trial enrollment and access to treatment with FGFR inhibitors.
Managing Cholangiocarcinoma in the Setting of COVID-19: Unique Challenges and Opportunities
By Ghassan K. Abou-Alfa, MD, MBA; Bruce Lin, MD; Farshid Dayyani, MD, PhD; Richard Kim, MD; Rachna T. Shroff, MD, MS; Melinda Bachini; Milind M. Javle, MD
December 2020, Special Issue: Managing CCA in the Setting of COVID-19
The first confirmed case in the United States of the 2019 novel coronavirus (COVID-19) was reported on January 21, 2020, and as of November 27, 2020, there were >63 million confirmed cases and >1.5 million deaths globally. Despite the global impact, certain populations have been identified as having a higher risk of developing severe COVID-19 infection, including patients with cancer. Various studies have shown that patients with cancer experience particularly poor outcomes after COVID-19 infection. As a result of the pandemic, care delivery has been disrupted to some degree based on the need for prioritization and limitations on resources. Therefore, healthcare providers and patients have been continually reassessing the balance between the benefits and risks of anticancer interventions in the context of the added risk of COVID-19 infection.
Cholangiocarcinoma Year in Review Introduction
2020 Year in Review: Cholangiocarcinoma
As a result of the COVID-19 pandemic, year 2020 has witnessed unprecedented changes in the practice of medicine. The effect on medical conferences has been equally dramatic, and several major meetings have been canceled or altered. Fortunately, the oncology community adapted quickly!
Toripalimab, Lenvatinib, plus Chemotherapy a Promising Combination in Advanced Unresectable Intrahepatic CCA
2020 Year in Review: Cholangiocarcinoma
The multidrug combination of toripalimab, lenvatinib plus chemotherapy with gemcitabine and oxaliplatin showed promising efficacy and tolerability in patients with intrahepatic CCA.
Comparison of the Clinical Features, Treatment Patterns, and Tumor Mutations of Patients with Intrahepatic and Extrahepatic CCA
2020 Year in Review: Cholangiocarcinoma
Retrospective chart review data indicate that intrahepatic CCA and extrahepatic CCA exhibit disparate clinical features and molecular profile, and divergent treatment patterns.
Institutional Review Data Indicate That Actionable Genetic Testing and Personalized Medicine in Hepatobiliary and Pancreatic Cancers Is Rarely Applied
2020 Year in Review: Cholangiocarcinoma
Real-world data indicate that genetic testing and personalized medicine is rarely applied in the community setting for patients with hepatobiliary and pancreatic cancers.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to recieve the free CCA News print publication or weekly e‑Newsletter.

I'd like to recieve: